Skip to main content
PMC home page
Mediators of Inflammation logoLink to Mediators of Inflammation
. 1997 Apr;6(2):95–103. doi: 10.1080/09629359791785

Cytokines in inflammatory bowel disease

P L Beck 1, J L Wallace 1,✉
PMCID: PMC2365859  PMID: 18472842

Abstract

Over the past decade, much has been learned regarding the role of various cytokines in the pathogenesis of inflammatory bowel disease. Several cytokine ‘knockout’ models in mice have been shown to develop colitis, while alterations in the production of various cytokines has been documented in human Crohn's disease and ulcerative colitis. In recent years, attempts have been made to treat these diseases through modulation of cytokine production or action. This review focuses on the cytokines that have been implicated in the pathogenesis of inflammatory bowel disease. The evidence for and against a role for particular cytokines in intestinal inflammation is reviewed, as is the experimental and clinical data suggesting that cytokines are rational targets for the development of new therapies.

Full Text

The Full Text of this article is available as a PDF (221.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Autschbach F., Schürmann G., Qiao L., Merz H., Wallich R., Meuer S. C. Cytokine messenger RNA expression and proliferation status of intestinal mononuclear cells in noninflamed gut and Crohn's disease. Virchows Arch. 1995;426(1):51–60. doi: 10.1007/BF00194698. [DOI] [PubMed] [Google Scholar]
  2. Baumann H., Gauldie J. The acute phase response. Immunol Today. 1994 Feb;15(2):74–80. doi: 10.1016/0167-5699(94)90137-6. [DOI] [PubMed] [Google Scholar]
  3. Bochner B. S., Klunk D. A., Sterbinsky S. A., Coffman R. L., Schleimer R. P. IL-13 selectively induces vascular cell adhesion molecule-1 expression in human endothelial cells. J Immunol. 1995 Jan 15;154(2):799–803. [PubMed] [Google Scholar]
  4. Booth C., Evans G. S., Potten C. S. Growth factor regulation of proliferation in primary cultures of small intestinal epithelium. In Vitro Cell Dev Biol Anim. 1995 Mar;31(3):234–243. doi: 10.1007/BF02639439. [DOI] [PubMed] [Google Scholar]
  5. Boughton-Smith N. K., Evans S. M., Hawkey C. J., Cole A. T., Balsitis M., Whittle B. J., Moncada S. Nitric oxide synthase activity in ulcerative colitis and Crohn's disease. Lancet. 1993 Aug 7;342(8867):338–340. doi: 10.1016/0140-6736(93)91476-3. [DOI] [PubMed] [Google Scholar]
  6. Brynskov J., Freund L., Nørby Rasmussen S., Lauritsen K., Schaffalitzky de Muckadell O., Williams C. N., MacDonald A. S., Tanton R., Molina F., Campanini M. C. Final report on a placebo-controlled, double-blind, randomized, multicentre trial of cyclosporin treatment in active chronic Crohn's disease. Scand J Gastroenterol. 1991 Jul;26(7):689–695. doi: 10.3109/00365529108998585. [DOI] [PubMed] [Google Scholar]
  7. Burd P. R., Thompson W. C., Max E. E., Mills F. C. Activated mast cells produce interleukin 13. J Exp Med. 1995 Apr 1;181(4):1373–1380. doi: 10.1084/jem.181.4.1373. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Casellas F., Papo M., Guarner F., Antolín M., Armengol J. R., Malagelada J. R. Intraluminal colonic release of immunoreactive tumour necrosis factor in chronic ulcerative colitis. Clin Sci (Lond) 1994 Oct;87(4):453–458. doi: 10.1042/cs0870453. [DOI] [PubMed] [Google Scholar]
  9. Casini-Raggi V., Kam L., Chong Y. J., Fiocchi C., Pizarro T. T., Cominelli F. Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation. J Immunol. 1995 Mar 1;154(5):2434–2440. [PubMed] [Google Scholar]
  10. Casini-Raggi V., Monsacchi L., Vosbeck K., Nast C. C., Pizarro T. T., Cominelli F. Anti-inflammatory effects of CGP 47969A, a novel inhibitor of proinflammatory cytokine synthesis, in rabbit immune colitis. Gastroenterology. 1995 Sep;109(3):812–818. doi: 10.1016/0016-5085(95)90388-7. [DOI] [PubMed] [Google Scholar]
  11. Cominelli F., Nast C. C., Clark B. D., Schindler R., Lierena R., Eysselein V. E., Thompson R. C., Dinarello C. A. Interleukin 1 (IL-1) gene expression, synthesis, and effect of specific IL-1 receptor blockade in rabbit immune complex colitis. J Clin Invest. 1990 Sep;86(3):972–980. doi: 10.1172/JCI114799. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Davidsen B., Munkholm P., Schlichting P., Nielsen O. H., Krarup H., Bonnevie-Nielsen V. Tolerability of interferon alpha-2b, a possible new treatment of active Crohn's disease. Aliment Pharmacol Ther. 1995 Feb;9(1):75–79. doi: 10.1111/j.1365-2036.1995.tb00355.x. [DOI] [PubMed] [Google Scholar]
  13. Del Prete G., De Carli M., Almerigogna F., Giudizi M. G., Biagiotti R., Romagnani S. Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J Immunol. 1993 Jan 15;150(2):353–360. [PubMed] [Google Scholar]
  14. Du X. X., Doerschuk C. M., Orazi A., Williams D. A. A bone marrow stromal-derived growth factor, interleukin-11, stimulates recovery of small intestinal mucosal cells after cytoablative therapy. Blood. 1994 Jan 1;83(1):33–37. [PubMed] [Google Scholar]
  15. Dubucquoi S., Janin A., Klein O., Desreumaux P., Quandalle P., Cortot A., Capron M., Colombel J. F. Activated eosinophils and interleukin 5 expression in early recurrence of Crohn's disease. Gut. 1995 Aug;37(2):242–246. doi: 10.1136/gut.37.2.242. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Elliott M. J., Maini R. N., Feldmann M., Kalden J. R., Antoni C., Smolen J. S., Leeb B., Breedveld F. C., Macfarlane J. D., Bijl H. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994 Oct 22;344(8930):1105–1110. doi: 10.1016/s0140-6736(94)90628-9. [DOI] [PubMed] [Google Scholar]
  17. Fais S., Capobianchi M. R., Silvestri M., Mercuri F., Pallone F., Dianzani F. Interferon expression in Crohn's disease patients: increased interferon-gamma and -alpha mRNA in the intestinal lamina propria mononuclear cells. J Interferon Res. 1994 Oct;14(5):235–238. doi: 10.1089/jir.1994.14.235. [DOI] [PubMed] [Google Scholar]
  18. Ferretti M., Casini-Raggi V., Pizarro T. T., Eisenberg S. P., Nast C. C., Cominelli F. Neutralization of endogenous IL-1 receptor antagonist exacerbates and prolongs inflammation in rabbit immune colitis. J Clin Invest. 1994 Jul;94(1):449–453. doi: 10.1172/JCI117345. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Gamble J. R., Khew-Goodall Y., Vadas M. A. Transforming growth factor-beta inhibits E-selectin expression on human endothelial cells. J Immunol. 1993 May 15;150(10):4494–4503. [PubMed] [Google Scholar]
  20. Gasché C., Reinisch W., Vogelsang H., Pötzi R., Markis E., Micksche M., Wirth H. P., Gangl A., Lochs H. Prospective evaluation of interferon-alpha in treatment of chronic active Crohn's disease. Dig Dis Sci. 1995 Apr;40(4):800–804. doi: 10.1007/BF02064982. [DOI] [PubMed] [Google Scholar]
  21. Gibson P., Rosella O. Interleukin 8 secretion by colonic crypt cells in vitro: response to injury suppressed by butyrate and enhanced in inflammatory bowel disease. Gut. 1995 Oct;37(4):536–543. doi: 10.1136/gut.37.4.536. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Gionchetti P., Campieri M., Belluzzi A., Bertinelli E., Ferretti M., Brignola C., Poggioli G., Miglioli M., Barbara L. Mucosal concentrations of interleukin-1 beta, interleukin-6, interleukin-8, and tumor necrosis factor-alpha in pelvic ileal pouches. Dig Dis Sci. 1994 Jul;39(7):1525–1531. doi: 10.1007/BF02088059. [DOI] [PubMed] [Google Scholar]
  23. Gurbindo C., Sabbah S., Menezes J., Justinich C., Marchand R., Seidman E. G. Interleukin-2 production in pediatric inflammatory bowel disease: evidence for dissimilar mononuclear cell function in Crohn's disease and ulcerative colitis. J Pediatr Gastroenterol Nutr. 1993 Oct;17(3):247–254. doi: 10.1097/00005176-199310000-00003. [DOI] [PubMed] [Google Scholar]
  24. Hadziselimovic F., Emmons L. R., Gallati H. Soluble tumour necrosis factor receptors p55 and p75 in the urine monitor disease activity and the efficacy of treatment of inflammatory bowel disease. Gut. 1995 Aug;37(2):260–263. doi: 10.1136/gut.37.2.260. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Holtkamp W., Stollberg T., Reis H. E. Serum interleukin-6 is related to disease activity but not disease specificity in inflammatory bowel disease. J Clin Gastroenterol. 1995 Mar;20(2):123–126. doi: 10.1097/00004836-199503000-00010. [DOI] [PubMed] [Google Scholar]
  26. Hyams J. S., Fitzgerald J. E., Wyzga N., Treem W. R., Justinich C. J., Kreutzer D. L. Characterization of circulating interleukin-1 receptor antagonist expression in children with inflammatory bowel disease. Dig Dis Sci. 1994 Sep;39(9):1893–1899. doi: 10.1007/BF02088122. [DOI] [PubMed] [Google Scholar]
  27. Karttunnen R., Breese E. J., Walker-Smith J. A., MacDonald T. T. Decreased mucosal interleukin-4 (IL-4) production in gut inflammation. J Clin Pathol. 1994 Nov;47(11):1015–1018. doi: 10.1136/jcp.47.11.1015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Kim C., Schinkel C., Fuchs D., Stadler J., Walz A., Zedler S., von Donnersmarck G. H., Faist E. Interleukin-13 effectively down-regulates the monocyte inflammatory potential during traumatic stress. Arch Surg. 1995 Dec;130(12):1330–1336. doi: 10.1001/archsurg.1995.01430120084013. [DOI] [PubMed] [Google Scholar]
  29. Kobayashi S., Teramura M., Oshimi K., Mizoguchi H. Interleukin-11. Leuk Lymphoma. 1994 Sep;15(1-2):45–49. doi: 10.3109/10428199409051676. [DOI] [PubMed] [Google Scholar]
  30. Kucharzik T., Stoll R., Lügering N., Domschke W. Circulating antiinflammatory cytokine IL-10 in patients with inflammatory bowel disease (IBD). Clin Exp Immunol. 1995 Jun;100(3):452–456. doi: 10.1111/j.1365-2249.1995.tb03721.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Kulkarni A. B., Karlsson S. Transforming growth factor-beta 1 knockout mice. A mutation in one cytokine gene causes a dramatic inflammatory disease. Am J Pathol. 1993 Jul;143(1):3–9. [PMC free article] [PubMed] [Google Scholar]
  32. Kühn R., Löhler J., Rennick D., Rajewsky K., Müller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell. 1993 Oct 22;75(2):263–274. doi: 10.1016/0092-8674(93)80068-p. [DOI] [PubMed] [Google Scholar]
  33. Lichtiger S., Present D. H., Kornbluth A., Gelernt I., Bauer J., Galler G., Michelassi F., Hanauer S. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994 Jun 30;330(26):1841–1845. doi: 10.1056/NEJM199406303302601. [DOI] [PubMed] [Google Scholar]
  34. Ligumsky M., Simon P. L., Karmeli F., Rachmilewitz D. Role of interleukin 1 in inflammatory bowel disease--enhanced production during active disease. Gut. 1990 Jun;31(6):686–689. doi: 10.1136/gut.31.6.686. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Madsen K. L., Tavernini M. M., Mosmann T. R., Fedorak R. N. Interleukin 10 modulates ion transport in rat small intestine. Gastroenterology. 1996 Oct;111(4):936–944. doi: 10.1016/s0016-5085(96)70061-6. [DOI] [PubMed] [Google Scholar]
  36. Manzano L., Alvarez-Mon M., Vargas J. A., Girón J. A., Abreu L., Fernández-Corugedo A., Román L. I., Albarran F., Durántez A. Deficient interleukin 2 dependent proliferation pathway in T lymphocytes from active and inactive ulcerative colitis patients. Gut. 1994 Jul;35(7):955–960. doi: 10.1136/gut.35.7.955. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Mazlam M. Z., Hodgson H. J. Interrelations between interleukin-6, interleukin-1 beta, plasma C-reactive protein values, and in vitro C-reactive protein generation in patients with inflammatory bowel disease. Gut. 1994 Jan;35(1):77–83. doi: 10.1136/gut.35.1.77. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. McCabe R. P., Secrist H., Botney M., Egan M., Peters M. G. Cytokine mRNA expression in intestine from normal and inflammatory bowel disease patients. Clin Immunol Immunopathol. 1993 Jan;66(1):52–58. doi: 10.1006/clin.1993.1007. [DOI] [PubMed] [Google Scholar]
  39. McCafferty D. M., Rioux K. J., Wallace J. L. Granulocyte infiltration in experimental colitis in the rat is interleukin-1 dependent and leukotriene independent. Eicosanoids. 1992;5(3-4):121–125. [PubMed] [Google Scholar]
  40. McCall R. D., Haskill S., Zimmermann E. M., Lund P. K., Thompson R. C., Sartor R. B. Tissue interleukin 1 and interleukin-1 receptor antagonist expression in enterocolitis in resistant and susceptible rats. Gastroenterology. 1994 Apr;106(4):960–972. doi: 10.1016/0016-5085(94)90755-2. [DOI] [PubMed] [Google Scholar]
  41. Mitsuyama K., Toyonaga A., Sasaki E., Ishida O., Ikeda H., Tsuruta O., Harada K., Tateishi H., Nishiyama T., Tanikawa K. Soluble interleukin-6 receptors in inflammatory bowel disease: relation to circulating interleukin-6. Gut. 1995 Jan;36(1):45–49. doi: 10.1136/gut.36.1.45. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Mitsuyama K., Toyonaga A., Sasaki E., Watanabe K., Tateishi H., Nishiyama T., Saiki T., Ikeda H., Tsuruta O., Tanikawa K. IL-8 as an important chemoattractant for neutrophils in ulcerative colitis and Crohn's disease. Clin Exp Immunol. 1994 Jun;96(3):432–436. doi: 10.1111/j.1365-2249.1994.tb06047.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Mullin G. E., Lazenby A. J., Harris M. L., Bayless T. M., James S. P. Increased interleukin-2 messenger RNA in the intestinal mucosal lesions of Crohn's disease but not ulcerative colitis. Gastroenterology. 1992 May;102(5):1620–1627. doi: 10.1016/0016-5085(92)91722-g. [DOI] [PubMed] [Google Scholar]
  44. Neben S., Turner K. The biology of interleukin 11. Stem Cells. 1993 Jul;11 (Suppl 2):156–162. doi: 10.1002/stem.5530110825. [DOI] [PubMed] [Google Scholar]
  45. Nishiyama T., Mitsuyama K., Toyonaga A., Sasaki E., Tanikawa K. Colonic mucosal interleukin 1 receptor antagonist in inflammatory bowel disease. Digestion. 1994;55(6):368–373. doi: 10.1159/000201167. [DOI] [PubMed] [Google Scholar]
  46. Onoe Y., Miyaura C., Kaminakayashiki T., Nagai Y., Noguchi K., Chen Q. R., Seo H., Ohta H., Nozawa S., Kudo I. IL-13 and IL-4 inhibit bone resorption by suppressing cyclooxygenase-2-dependent prostaglandin synthesis in osteoblasts. J Immunol. 1996 Jan 15;156(2):758–764. [PubMed] [Google Scholar]
  47. Patel R. T., Bain I., Youngs D., Keighley M. R. Cytokine production in pouchitis is similar to that in ulcerative colitis. Dis Colon Rectum. 1995 Aug;38(8):831–837. doi: 10.1007/BF02049839. [DOI] [PubMed] [Google Scholar]
  48. Potten C. S. Interleukin-11 protects the clonogenic stem cells in murine small-intestinal crypts from impairment of their reproductive capacity by radiation. Int J Cancer. 1995 Jul 28;62(3):356–361. doi: 10.1002/ijc.2910620321. [DOI] [PubMed] [Google Scholar]
  49. Potten C. S., Owen G., Hewitt D., Chadwick C. A., Hendry H., Lord B. I., Woolford L. B. Stimulation and inhibition of proliferation in the small intestinal crypts of the mouse after in vivo administration of growth factors. Gut. 1995 Jun;36(6):864–873. doi: 10.1136/gut.36.6.864. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Pullan R. D., Rhodes J., Ganesh S., Mani V., Morris J. S., Williams G. T., Newcombe R. G., Russell M. A., Feyerabend C., Thomas G. A. Transdermal nicotine for active ulcerative colitis. N Engl J Med. 1994 Mar 24;330(12):811–815. doi: 10.1056/NEJM199403243301202. [DOI] [PubMed] [Google Scholar]
  51. Qiu B. S., Pfeiffer C. J., Keith J. C., Jr Protection by recombinant human interleukin-11 against experimental TNB-induced colitis in rats. Dig Dis Sci. 1996 Aug;41(8):1625–1630. doi: 10.1007/BF02087911. [DOI] [PubMed] [Google Scholar]
  52. Raab Y., Sundberg C., Hällgren R., Knutson L., Gerdin B. Mucosal synthesis and release of prostaglandin E2 from activated eosinophils and macrophages in ulcerative colitis. Am J Gastroenterol. 1995 Apr;90(4):614–620. [PubMed] [Google Scholar]
  53. Reinecker H. C., Steffen M., Witthoeft T., Pflueger I., Schreiber S., MacDermott R. P., Raedler A. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol. 1993 Oct;94(1):174–181. doi: 10.1111/j.1365-2249.1993.tb05997.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Sartor R. B. Cytokines in intestinal inflammation: pathophysiological and clinical considerations. Gastroenterology. 1994 Feb;106(2):533–539. doi: 10.1016/0016-5085(94)90614-9. [DOI] [PubMed] [Google Scholar]
  55. Schlaak J. F., Schwarting A., Knolle P., Meyer zum Büschenfelde K. H., Mayet W. Effects of Th1 and Th2 cytokines on cytokine production and ICAM-1 expression on synovial fibroblasts. Ann Rheum Dis. 1995 Jul;54(7):560–565. doi: 10.1136/ard.54.7.560. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Schreiber S., Heinig T., Panzer U., Reinking R., Bouchard A., Stahl P. D., Raedler A. Impaired response of activated mononuclear phagocytes to interleukin 4 in inflammatory bowel disease. Gastroenterology. 1995 Jan;108(1):21–33. doi: 10.1016/0016-5085(95)90004-7. [DOI] [PubMed] [Google Scholar]
  57. Schreiber S., Heinig T., Thiele H. G., Raedler A. Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology. 1995 May;108(5):1434–1444. doi: 10.1016/0016-5085(95)90692-4. [DOI] [PubMed] [Google Scholar]
  58. Sher M. E., D'Angelo A. J., Stein T. A., Bailey B., Burns G., Wise L. Cytokines in Crohn's colitis. Am J Surg. 1995 Jan;169(1):133–136. doi: 10.1016/s0002-9610(99)80121-4. [DOI] [PubMed] [Google Scholar]
  59. Sparano J. A., Brandt L. J., Dutcher J. P., DuBois J. S., Atkins M. B. Symptomatic exacerbation of Crohn disease after treatment with high-dose interleukin-2. Ann Intern Med. 1993 Apr 15;118(8):617–618. doi: 10.7326/0003-4819-118-8-199304150-00007. [DOI] [PubMed] [Google Scholar]
  60. Thomas G. A., Rhodes J., Mani V., Williams G. T., Newcombe R. G., Russell M. A., Feyerabend C. Transdermal nicotine as maintenance therapy for ulcerative colitis. N Engl J Med. 1995 Apr 13;332(15):988–992. doi: 10.1056/NEJM199504133321503. [DOI] [PubMed] [Google Scholar]
  61. Turner M., Chantry D., Katsikis P., Berger A., Brennan F. M., Feldmann M. Induction of the interleukin 1 receptor antagonist protein by transforming growth factor-beta. Eur J Immunol. 1991 Jul;21(7):1635–1639. doi: 10.1002/eji.1830210708. [DOI] [PubMed] [Google Scholar]
  62. Van Dijk J. P., Madretsma G. S., Keuskamp Z. J., Zijlstra F. J. Nicotine inhibits cytokine synthesis by mouse colonic mucosa. Eur J Pharmacol. 1995 May 4;278(1):R11–R12. doi: 10.1016/0014-2999(95)00211-3. [DOI] [PubMed] [Google Scholar]
  63. Vodovotz Y., Bogdan C., Paik J., Xie Q. W., Nathan C. Mechanisms of suppression of macrophage nitric oxide release by transforming growth factor beta. J Exp Med. 1993 Aug 1;178(2):605–613. doi: 10.1084/jem.178.2.605. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Yano S., Sone S., Nishioka Y., Mukaida N., Matsushima K., Ogura T. Differential effects of anti-inflammatory cytokines (IL-4, IL-10 and IL-13) on tumoricidal and chemotactic properties of human monocytes induced by monocyte chemotactic and activating factor. J Leukoc Biol. 1995 Feb;57(2):303–309. doi: 10.1002/jlb.57.2.303. [DOI] [PubMed] [Google Scholar]
  65. van Dullemen H. M., van Deventer S. J., Hommes D. W., Bijl H. A., Jansen J., Tytgat G. N., Woody J. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology. 1995 Jul;109(1):129–135. doi: 10.1016/0016-5085(95)90277-5. [DOI] [PubMed] [Google Scholar]

Articles from Mediators of Inflammation are provided here courtesy of Wiley

RESOURCES